| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyBiologicalProcess | RIG-I signaling pathway | 1.21e-05 | 30 | 31 | 3 | GO:0039529 | |
| GeneOntologyBiologicalProcess | stress granule assembly | 2.12e-05 | 36 | 31 | 3 | GO:0034063 | |
| GeneOntologyBiologicalProcess | positive regulation of RIG-I signaling pathway | 1.19e-04 | 11 | 31 | 2 | GO:1900246 | |
| GeneOntologyBiologicalProcess | positive regulation of miRNA-mediated gene silencing | 1.43e-04 | 12 | 31 | 2 | GO:2000637 | |
| GeneOntologyBiologicalProcess | regulation of stress granule assembly | 1.43e-04 | 12 | 31 | 2 | GO:0062028 | |
| GeneOntologyBiologicalProcess | positive regulation of post-transcriptional gene silencing by RNA | 1.69e-04 | 13 | 31 | 2 | GO:1900370 | |
| GeneOntologyBiologicalProcess | positive regulation of post-transcriptional gene silencing | 1.69e-04 | 13 | 31 | 2 | GO:0060148 | |
| GeneOntologyBiologicalProcess | positive regulation of pattern recognition receptor signaling pathway | 2.25e-04 | 79 | 31 | 3 | GO:0062208 | |
| GeneOntologyBiologicalProcess | magnesium ion homeostasis | 2.93e-04 | 17 | 31 | 2 | GO:0010960 | |
| GeneOntologyBiologicalProcess | 3'-UTR-mediated mRNA destabilization | 3.68e-04 | 19 | 31 | 2 | GO:0061158 | |
| GeneOntologyCellularComponent | cytoplasmic stress granule | 1.19e-05 | 96 | 31 | 4 | GO:0010494 | |
| GeneOntologyCellularComponent | cytoplasmic ribonucleoprotein granule | 6.42e-04 | 269 | 31 | 4 | GO:0036464 | |
| GeneOntologyCellularComponent | ribonucleoprotein granule | 8.17e-04 | 287 | 31 | 4 | GO:0035770 | |
| Domain | Pumilio_RNA-bd | 2.67e-06 | 2 | 31 | 2 | IPR033712 | |
| Domain | PUM-HD | 7.99e-06 | 3 | 31 | 2 | IPR033133 | |
| Domain | PUF | 7.99e-06 | 3 | 31 | 2 | PF00806 | |
| Domain | PUM_HD | 7.99e-06 | 3 | 31 | 2 | PS50303 | |
| Domain | Pumilio_RNA-bd_rpt | 1.60e-05 | 4 | 31 | 2 | IPR001313 | |
| Domain | PUM | 1.60e-05 | 4 | 31 | 2 | PS50302 | |
| Domain | Pumilio | 1.60e-05 | 4 | 31 | 2 | SM00025 | |
| Domain | CUB | 7.24e-05 | 49 | 31 | 3 | PF00431 | |
| Domain | CUB | 7.70e-05 | 50 | 31 | 3 | SM00042 | |
| Domain | Sushi | 8.66e-05 | 52 | 31 | 3 | PF00084 | |
| Domain | - | 8.66e-05 | 52 | 31 | 3 | 2.60.120.290 | |
| Domain | CUB | 9.17e-05 | 53 | 31 | 3 | PS01180 | |
| Domain | CCP | 9.70e-05 | 54 | 31 | 3 | SM00032 | |
| Domain | SUSHI | 1.08e-04 | 56 | 31 | 3 | PS50923 | |
| Domain | Sushi_SCR_CCP_dom | 1.14e-04 | 57 | 31 | 3 | IPR000436 | |
| Domain | CUB_dom | 1.14e-04 | 57 | 31 | 3 | IPR000859 | |
| Domain | PH_dom-like | 5.16e-03 | 426 | 31 | 4 | IPR011993 | |
| Domain | CH | 5.20e-03 | 65 | 31 | 2 | SM00033 | |
| Domain | CH | 6.00e-03 | 70 | 31 | 2 | PF00307 | |
| Domain | - | 6.17e-03 | 71 | 31 | 2 | 1.10.418.10 | |
| Domain | CH | 6.51e-03 | 73 | 31 | 2 | PS50021 | |
| Domain | CH-domain | 6.86e-03 | 75 | 31 | 2 | IPR001715 | |
| Pubmed | 6.41e-10 | 3 | 31 | 3 | 12906867 | ||
| Pubmed | 5.89e-08 | 407 | 31 | 7 | 12693553 | ||
| Pubmed | A central chaperone-like role for 14-3-3 proteins in human cells. | 6.50e-07 | 861 | 31 | 8 | 36931259 | |
| Pubmed | A genetic association study of CSMD1 and CSMD2 with cognitive function. | 7.69e-07 | 2 | 31 | 2 | 27890662 | |
| Pubmed | A Quantitative and Predictive Model for RNA Binding by Human Pumilio Proteins. | 7.69e-07 | 2 | 31 | 2 | 31078383 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 32753408 | ||
| Pubmed | The complement control-related genes CSMD1 and CSMD2 associate to schizophrenia. | 7.69e-07 | 2 | 31 | 2 | 21439553 | |
| Pubmed | Loss of CSMD1 or 2 may contribute to the poor prognosis of colorectal cancer patients. | 7.69e-07 | 2 | 31 | 2 | 24408017 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 12459267 | ||
| Pubmed | PUMILIO proteins promote colorectal cancer growth via suppressing p21. | 7.69e-07 | 2 | 31 | 2 | 35338151 | |
| Pubmed | Identification of diverse target RNAs that are functionally regulated by human Pumilio proteins. | 7.69e-07 | 2 | 31 | 2 | 29165587 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 32437472 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 35507203 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 26517885 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 12667987 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 12771951 | ||
| Pubmed | Alternate modes of cognate RNA recognition by human PUMILIO proteins. | 7.69e-07 | 2 | 31 | 2 | 21397187 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 18776931 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 32316190 | ||
| Pubmed | 1.61e-06 | 225 | 31 | 5 | 12168954 | ||
| Pubmed | Antagonistic and cooperative AGO2-PUM interactions in regulating mRNAs. | 2.31e-06 | 3 | 31 | 2 | 30333515 | |
| Pubmed | Human Pumilio proteins directly bind the CCR4-NOT deadenylase complex to regulate the transcriptome. | 2.31e-06 | 3 | 31 | 2 | 33397688 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 27157388 | ||
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 38427913 | ||
| Pubmed | A novel function of human Pumilio proteins in cytoplasmic sensing of viral infection. | 2.31e-06 | 3 | 31 | 2 | 25340845 | |
| Pubmed | PUMILIO/FOXP1 signaling drives expansion of hematopoietic stem/progenitor and leukemia cells. | 2.31e-06 | 3 | 31 | 2 | 28232582 | |
| Pubmed | Noncoding RNA NORAD Regulates Genomic Stability by Sequestering PUMILIO Proteins. | 2.31e-06 | 3 | 31 | 2 | 26724866 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 22345517 | ||
| Pubmed | 4.20e-06 | 274 | 31 | 5 | 34244482 | ||
| Pubmed | 4.61e-06 | 4 | 31 | 2 | 30811992 | ||
| Pubmed | Target RNA motif and target mRNAs of the Quaking STAR protein. | 4.61e-06 | 4 | 31 | 2 | 16041388 | |
| Pubmed | 7.68e-06 | 5 | 31 | 2 | 30269240 | ||
| Pubmed | An Important Role of Pumilio 1 in Regulating the Development of the Mammalian Female Germline. | 7.68e-06 | 5 | 31 | 2 | 27170441 | |
| Pubmed | N-glycanase NGLY1 regulates mitochondrial homeostasis and inflammation through NRF1. | 7.68e-06 | 5 | 31 | 2 | 30135079 | |
| Pubmed | The RNA-binding protein Musashi-1 is produced in the developing and adult mouse eye. | 1.15e-05 | 6 | 31 | 2 | 17768378 | |
| Pubmed | 1.15e-05 | 6 | 31 | 2 | 32198202 | ||
| Pubmed | 1.61e-05 | 7 | 31 | 2 | 25100735 | ||
| Pubmed | 1.61e-05 | 7 | 31 | 2 | 34678304 | ||
| Pubmed | 2.46e-05 | 63 | 31 | 3 | 11572484 | ||
| Pubmed | High-throughput analyses of hnRNP H1 dissects its multi-functional aspect. | 2.61e-05 | 1021 | 31 | 7 | 26760575 | |
| Pubmed | 2.76e-05 | 9 | 31 | 2 | 35678316 | ||
| Pubmed | The mammalian TRIM-NHL protein TRIM71/LIN-41 is a repressor of mRNA function. | 3.44e-05 | 10 | 31 | 2 | 23125361 | |
| Pubmed | 3.44e-05 | 10 | 31 | 2 | 31048766 | ||
| Pubmed | 3.83e-05 | 1084 | 31 | 7 | 11544199 | ||
| Pubmed | 4.21e-05 | 11 | 31 | 2 | 16429158 | ||
| Pubmed | 5.96e-05 | 13 | 31 | 2 | 12511597 | ||
| Pubmed | 7.30e-05 | 497 | 31 | 5 | 23414517 | ||
| Pubmed | OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ. | 7.39e-05 | 91 | 31 | 3 | 30472188 | |
| Pubmed | The RNA-binding protein Snd1/Tudor-SN regulates hypoxia-responsive gene expression. | 8.93e-05 | 97 | 31 | 3 | 37151849 | |
| Pubmed | Essential requirement of mammalian Pumilio family in embryonic development. | 9.16e-05 | 16 | 31 | 2 | 30256721 | |
| Pubmed | Functional analysis of candidate genes from genome-wide association studies of hearing. | 1.04e-04 | 17 | 31 | 2 | 31927188 | |
| Pubmed | PTPN14 is required for the density-dependent control of YAP1. | 1.60e-04 | 21 | 31 | 2 | 22948661 | |
| Pubmed | 1.76e-04 | 22 | 31 | 2 | 26589352 | ||
| Pubmed | Assembly of the WHIP-TRIM14-PPP6C Mitochondrial Complex Promotes RIG-I-Mediated Antiviral Signaling. | 2.09e-04 | 332 | 31 | 4 | 29053956 | |
| Pubmed | 2.86e-04 | 28 | 31 | 2 | 18839057 | ||
| Pubmed | Post-transcriptional regulation of mouse neurogenesis by Pumilio proteins. | 3.08e-04 | 29 | 31 | 2 | 28794184 | |
| Pubmed | 3.43e-04 | 153 | 31 | 3 | 10718198 | ||
| Pubmed | A dual-activity topoisomerase complex regulates mRNA translation and turnover. | 3.78e-04 | 1105 | 31 | 6 | 35748872 | |
| Pubmed | 4.42e-04 | 733 | 31 | 5 | 34672954 | ||
| Pubmed | 4.49e-04 | 35 | 31 | 2 | 25343990 | ||
| Pubmed | Quantifying domain-ligand affinities and specificities by high-throughput holdup assay. | 4.75e-04 | 36 | 31 | 2 | 26053890 | |
| Pubmed | 5.14e-04 | 421 | 31 | 4 | 36976175 | ||
| Pubmed | 7.11e-04 | 44 | 31 | 2 | 27505670 | ||
| Pubmed | 7.11e-04 | 44 | 31 | 2 | 20200978 | ||
| Interaction | SFN interactions | 6.45e-07 | 692 | 31 | 9 | int:SFN | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr1p35 | 3.88e-03 | 137 | 31 | 2 | chr1p35 | |
| GeneFamily | Hyalectan proteoglycans|V-set domain containing|Sushi domain containing|C-type lectin domain containing | 3.80e-05 | 57 | 21 | 3 | 1179 | |
| Coexpression | GSE32255_UNSTIM_VS_4H_LPS_STIM_DC_DN | 9.85e-07 | 154 | 31 | 5 | M8912 | |
| ToppCell | TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-5|TCGA-Ovary / Sample_Type by Project: Shred V9 | 5.20e-06 | 166 | 31 | 4 | 32d2eaf8a5d03881bf74d680825af2d5110b082d | |
| ToppCell | ASK428-Immune-B_cell|Immune / Donor, Lineage and Cell class of Lung cells from Dropseq | 6.41e-06 | 175 | 31 | 4 | e0979e5795a49b4e5c9b88e7fe6b7bda7a413a6c | |
| ToppCell | TCGA-Brain-Primary_Tumor-Low_Grade_Glioma|TCGA-Brain / Sample_Type by Project: Shred V9 | 6.70e-06 | 177 | 31 | 4 | e8ab340b20cd41554c3841fe980e078e878af35f | |
| ToppCell | 3'-Parenchyma_lung-Endothelial-Blood_vessel_EC-pulmonary_artery_endothelial_cell-EC_arterial-EC_arterial_L.2.4.1.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 7.01e-06 | 179 | 31 | 4 | d2db9e70b780643f1e004c41a70464d0abe26088 | |
| ToppCell | COVID-19-Epithelial-Ionocytes|COVID-19 / Condition, Lineage and Cell class | 8.51e-06 | 188 | 31 | 4 | a581cb9528d0febbf3addbb4f6bc140f91a584e6 | |
| ToppCell | NS-critical-LOC-Epithelial-Secretory|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 9.82e-06 | 195 | 31 | 4 | b0d782eeee30c797b4da9b3be29b864983fd9e71 | |
| ToppCell | Parenchyma_Control_(B.)-Epithelial-TX-Basal_2|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type | 1.04e-05 | 198 | 31 | 4 | 686eda427b075e788de38149eae82faf19bd5704 | |
| ToppCell | Lung_Parenchyma-Control-Epithelial-Epithelial-Basal_2-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.04e-05 | 198 | 31 | 4 | a54ae5275a510b49d7629f0908817a0c5f05020e | |
| ToppCell | Lung_Parenchyma-Control-Epithelial-Epithelial-Basal_2|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.04e-05 | 198 | 31 | 4 | 34997e3896d0893fbe51bfb0d4660ccaca1c975e | |
| ToppCell | Tracheal-10x5prime-Epithelial-Epi_airway_secretory|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.06e-05 | 199 | 31 | 4 | 7223f853335492ca617dbec3e4b6872a8a463a45 | |
| ToppCell | Tracheal|World / Cell types per location group and 10X technology with lineage, and cell group designations | 1.09e-05 | 200 | 31 | 4 | 682960e28542a3d6c119047cd0131941932cfdea | |
| ToppCell | frontal_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Rspo1_Itga4|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.35e-04 | 144 | 31 | 3 | 7de962346ba9653d90dd13bb7d977fe44d200bba | |
| ToppCell | COVID-19-kidney-Technical/muscle_(PCT)|kidney / Disease (COVID-19 only), tissue and cell type | 1.41e-04 | 146 | 31 | 3 | c55f1bdb6ac43b4118cb27ea7c879527e1afcbab | |
| ToppCell | frontal_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Arhgap36_Hmcn1|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.62e-04 | 153 | 31 | 3 | 9c6fce56300ba5053efda59a438d63a808c497c0 | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Rspo4_Rxfp1_Chat|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.68e-04 | 155 | 31 | 3 | 3b8def9e8f66511736ea37f259511f7c8b7743af | |
| ToppCell | COVID-19-kidney-Technical/muscle_(Mes)|kidney / Disease (COVID-19 only), tissue and cell type | 1.81e-04 | 159 | 31 | 3 | 5335cbcdeaf2bbd0268bbfe0e45c8c0d288e640d | |
| ToppCell | frontal_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Pygm_C1ql1|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.88e-04 | 161 | 31 | 3 | 3b5d7a3dab479c6959a428f3954dedd989900276 | |
| ToppCell | Basal_cells-IPF_04|World / lung cells shred on cell class, cell subclass, sample id | 1.95e-04 | 163 | 31 | 3 | 679e25e5548d157d49a73057a3b5617dccda260f | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Epithelial-epithelial_progenitor_cell-Distal_progenitor|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.98e-04 | 164 | 31 | 3 | d6f71d804bb65301c02ea4e6673e20688b5fcd5b | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Crispld2_Htr2c|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 2.02e-04 | 165 | 31 | 3 | c6b23013d77fa9aa967b76e451c8e42b0a657c30 | |
| ToppCell | facs-Marrow-B-cells-24m-Myeloid-basophil|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.05e-04 | 166 | 31 | 3 | b21e45bd43f26149b9cd6e45c19241c82d54fb2f | |
| ToppCell | facs-Marrow-B-cells-24m-Myeloid-basophil|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.05e-04 | 166 | 31 | 3 | 13027ae342994db4540e64eb910df1f42b160931 | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Arhgap36_Hmcn1|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 2.09e-04 | 167 | 31 | 3 | 1c1b4722c6c0eff85a9b32ca7b4e281caebf63b0 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Degenerative_Proximal_Tubule_Epithelial_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.09e-04 | 167 | 31 | 3 | 3edb0570e583bb527165bcd8a4c25a042054043b | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.20e-04 | 170 | 31 | 3 | 2d880223d01bde4bf777bd6f50b7d2768489075f | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting-Basal_resting_L.0.0.0.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.20e-04 | 170 | 31 | 3 | 0cc20322cb3e3e7bbd4daad8785c99f80e355c16 | |
| ToppCell | frontal_cortex-Neuronal-GABAergic_neuron-Vip|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 2.24e-04 | 171 | 31 | 3 | 5efd15300f865ebf651e0888265cbd717bc3b9d3 | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Vip|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 2.28e-04 | 172 | 31 | 3 | 7e1a7700a4c2b1d100da1d6e475e73498ebb605a | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.4|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.32e-04 | 173 | 31 | 3 | 176b956e71d98e8275d698b39437fc326e5fe449 | |
| ToppCell | ASK428-Immune-B_cell|ASK428 / Donor, Lineage and Cell class of Lung cells from Dropseq | 2.36e-04 | 174 | 31 | 3 | b5a7a612a515736cf3489afd0f6ad2054d54526f | |
| ToppCell | Nasal_Brush-Epithelial-Basal_2|Nasal_Brush / Tissue, Lineage and Cell class of Lung Cells from 10X | 2.44e-04 | 176 | 31 | 3 | fc5787946f5a10056d326d070620575ae4081836 | |
| ToppCell | Nasal_Brush-Epithelial-Basal_2|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X | 2.44e-04 | 176 | 31 | 3 | 5daaba0853afe7d20d4635169ccd4f96e735b938 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.52e-04 | 178 | 31 | 3 | a0ab20c588e7d43d0320d4779d9ab95c1c86e297 | |
| ToppCell | 3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.5|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.56e-04 | 179 | 31 | 3 | 6e965e424eebef50f0202cff75f458be395cfca1 | |
| ToppCell | RV|World / Chamber and Cluster_Paper | 2.65e-04 | 181 | 31 | 3 | bbe1e6e59d8889bd37d6e8303116cbdcafca7236 | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Neuronal-Glial_immature-Glia_2_(ELN+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.65e-04 | 181 | 31 | 3 | 098dbb3e0ff531c9720a233123250c1e39a97d4c | |
| ToppCell | COVID-19-Heart-CM_3|Heart / Disease (COVID-19 only), tissue and cell type | 2.69e-04 | 182 | 31 | 3 | 287fcc3897ae08841f6f85ae6c9cef16f75b1dd1 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.87e-04 | 186 | 31 | 3 | a95744b8649096bd7cfc3591a02841fa411085b3 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.87e-04 | 186 | 31 | 3 | 4780af76237d7af2abbe2d8d5530cdf53e3ed0b7 | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.87e-04 | 186 | 31 | 3 | 23b8d51d20b05795a73892d3e20e0f9b6a207820 | |
| ToppCell | RV-04._Ventricular_Cardiomyocyte_I|World / Chamber and Cluster_Paper | 2.92e-04 | 187 | 31 | 3 | 78cdcf8bc141d3b155c3c8af908431fc419c4d08 | |
| ToppCell | facs-Heart-LA-18m-Mesenchymal-smooth_muscle_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.92e-04 | 187 | 31 | 3 | f1e9877d859369b862d4a559ec9ab9be74a67a96 | |
| ToppCell | facs-Heart-LA-18m-Mesenchymal-smooth_muscle_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.92e-04 | 187 | 31 | 3 | 3ffbd50b49059dcd3e23c5ac01901e4352142446 | |
| ToppCell | LV-04._Ventricular_Cardiomyocyte_I|World / Chamber and Cluster_Paper | 2.96e-04 | 188 | 31 | 3 | 0758b474457efa36488e0195f7357100f4b6a090 | |
| ToppCell | RV-06._Ventricular_Cardiomyocyte_II|World / Chamber and Cluster_Paper | 3.01e-04 | 189 | 31 | 3 | 5e80c47f63980904c4c1ff02c201b67b456a0974 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.01e-04 | 189 | 31 | 3 | 5d902a4660a27548764bf04c6de152b565da835c | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.01e-04 | 189 | 31 | 3 | 8c8ca3b30d9be6c854615459a7bfba82b427c8bc | |
| ToppCell | RV-04._Ventricular_Cardiomyocyte_I|RV / Chamber and Cluster_Paper | 3.01e-04 | 189 | 31 | 3 | 9c1debd65c13d63fd4f3158917d621b44b714c26 | |
| ToppCell | COVID-19-Epithelial_cells-Airway_goblet|COVID-19 / group, cell type (main and fine annotations) | 3.05e-04 | 190 | 31 | 3 | 51ca9ef4df3220487152fcf684147730637c7cc1 | |
| ToppCell | RV-06._Ventricular_Cardiomyocyte_II|RV / Chamber and Cluster_Paper | 3.05e-04 | 190 | 31 | 3 | fe8e78922c8ae928ef9a80bffd67868d5a87a091 | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.05e-04 | 190 | 31 | 3 | 73d94fbae92029745989a8712eed8b99fd84c193 | |
| ToppCell | LA-03._Atrial_Cardiomyocyte|LA / Chamber and Cluster_Paper | 3.10e-04 | 191 | 31 | 3 | 5d1b674eb7703830b7ce8bbeac3363cabd0e6ae9 | |
| ToppCell | LV-04._Ventricular_Cardiomyocyte_I|LV / Chamber and Cluster_Paper | 3.15e-04 | 192 | 31 | 3 | ad19e2c1d36a0566c9b12ced10db78f4781c8ea6 | |
| ToppCell | 5'-GW_trimst-2-SmallIntestine-Mesenchymal-myocytic-SMC_(PLPP2+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.20e-04 | 193 | 31 | 3 | 173f1d83133f5ffa88e2a75d28835ad7acd2aa90 | |
| ToppCell | 3'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.20e-04 | 193 | 31 | 3 | 605fc2a25ed6846fb283b2918cfed98df6039d6b | |
| ToppCell | COVID-19-Heart-CM_+_EC_+_Pericyte|Heart / Disease (COVID-19 only), tissue and cell type | 3.20e-04 | 193 | 31 | 3 | dd5378a1ef8eb0eda9a3aae62f3c2f3a1402bda0 | |
| ToppCell | RA-03._Atrial_Cardiomyocyte|RA / Chamber and Cluster_Paper | 3.25e-04 | 194 | 31 | 3 | c3535f7cc0076653c72db582047cff053c322397 | |
| ToppCell | Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.30e-04 | 195 | 31 | 3 | 19853c654ac64b3ae3bc99841c6cb29c8aaba85c | |
| ToppCell | COVID-19-Heart-CM_2|Heart / Disease (COVID-19 only), tissue and cell type | 3.30e-04 | 195 | 31 | 3 | 75fc81bddb246dca3b437fb60827b1d4fe416405 | |
| ToppCell | 3'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(nasal)-Club_(nasal)_L.0.2.3.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.30e-04 | 195 | 31 | 3 | 3f8ed20ad17afe1545e574e5ca5fe33c3704c7f3 | |
| ToppCell | Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic-neutrophil|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.30e-04 | 195 | 31 | 3 | d3755929ebbbf5e3afde44281e9056ddb614a291 | |
| ToppCell | Secretory|World / shred by cell class for bronchial biopsy | 3.30e-04 | 195 | 31 | 3 | 52f8281fe0df67cec3faa780a23ed6343ed5a6ba | |
| ToppCell | (05)_Secretory|World / shred by cell type by condition | 3.34e-04 | 196 | 31 | 3 | 8032c25b51ef96aeba28cc52686a2bd45213453d | |
| ToppCell | COVID-19-Heart-Mito_CM|COVID-19 / Disease (COVID-19 only), tissue and cell type | 3.40e-04 | 197 | 31 | 3 | 44e49943d62bfe622b40ad0460093d31540544df | |
| ToppCell | NS-critical-d_16-33-Epithelial-Secretory|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 3.40e-04 | 197 | 31 | 3 | a72047b7428c0d4aaf016c1ac23dc30919260fd8 | |
| ToppCell | PSB-critical-LOC-Epithelial-Secretory|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 3.45e-04 | 198 | 31 | 3 | e4cbe4032dba0da3fd46817ea9ad86ba9217f747 | |
| ToppCell | LPS_IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 3.45e-04 | 198 | 31 | 3 | b598ab958e31f1e98bd06dc0097b58ac3a3f90a3 | |
| ToppCell | moderate-Epithelial-Secretory|moderate / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 3.45e-04 | 198 | 31 | 3 | 7d96d7105a849c7280ce87bd76ce130ac47384fd | |
| ToppCell | Control_saline-Epithelial_alveolar-AT_1-Differentiating_AT1|Control_saline / Treatment groups by lineage, cell group, cell type | 3.45e-04 | 198 | 31 | 3 | 85f424cd9bb3117c9e322031024aabb87696ce47 | |
| ToppCell | Parenchymal-10x5prime-Epithelial-Epi_airway_basal-Suprabasal|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 3.45e-04 | 198 | 31 | 3 | de5987588b9fa9ee8c595ba06d7d844ead0e3c74 | |
| ToppCell | LPS_anti-TNF-Epithelial_alveolar-AT_1-AT1|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 3.45e-04 | 198 | 31 | 3 | 1282db321e27499d310339d6383974614e295a20 | |
| ToppCell | Bronchial-NucSeq-Epithelial-Epi_submucosal-gland-SMG_Duct|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 3.45e-04 | 198 | 31 | 3 | 1fe60443c11d34b6d2671af8f06e0dedc8d1558b | |
| ToppCell | LPS_anti-TNF-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 3.50e-04 | 199 | 31 | 3 | d43c605a4ff221cf78d91678c15d2ad20f831c7f | |
| ToppCell | LPS_IL1RA_TNF-Epithelial_alveolar-AT_1|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 3.50e-04 | 199 | 31 | 3 | 1c70e7d6bd25980e1b92aa1cac3f3c95d9651b4b | |
| ToppCell | LPS_IL1RA-Epithelial_alveolar-AT_1|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 3.50e-04 | 199 | 31 | 3 | a270630626df614f8605abddb7dee7c4d74f6149 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC-OPC-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.50e-04 | 199 | 31 | 3 | 19a97e27a4758e794ce7246d295e112b47931a48 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.50e-04 | 199 | 31 | 3 | 333056c2abe9724efeab542c0365fcfe4eff8f18 | |
| ToppCell | Tracheal-10x5prime-Epithelial-Epi_airway_secretory-Secretory_Goblet|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 3.50e-04 | 199 | 31 | 3 | e03bdc7cb825e287f41b834ec6061d23c1c03b04 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC-OPC|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.50e-04 | 199 | 31 | 3 | e60ecbb8fa7bcd3e2ce7d78f6efb2cfd1fd77698 | |
| ToppCell | Biopsy_Other_PF-Epithelial-MUC5B+|Biopsy_Other_PF / Sample group, Lineage and Cell type | 3.50e-04 | 199 | 31 | 3 | afd0df242a93f176438309668a9487be1250d9ca | |
| ToppCell | LPS_IL1RA_TNF-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 3.55e-04 | 200 | 31 | 3 | ddfb1f006365bf16203ee49f20200f68220cc288 | |
| ToppCell | Parenchyma_COVID-19-Epithelial-TX-Club|Parenchyma_COVID-19 / Sample group, Lineage and Cell type | 3.55e-04 | 200 | 31 | 3 | 85f946dd3831acf3488c87efba96689cc2667c3a | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA----L1-6|Macroglial / cells hierarchy compared to all cells using T-Statistic | 3.55e-04 | 200 | 31 | 3 | 310cd53db1c137f6af74e6ae682221d7ac27310c | |
| ToppCell | Bronchial-NucSeq-Epithelial-Epi_submucosal-gland-SMG_Mucous|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 3.55e-04 | 200 | 31 | 3 | ed093626a9cac7531a2bf02f6e345c5e84b8c060 | |
| ToppCell | Lung_Parenchyma-Severe-Epithelial-Epithelial-Club-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.55e-04 | 200 | 31 | 3 | 8a44a4f7ea9358f2194a490e79601c98ff7fdcb0 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_myocytic-Pericyte-Pericyte_3|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 3.55e-04 | 200 | 31 | 3 | 9169a9ec8e9ab95d90a64c5a19ac666a5cf82313 | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA|Macroglial / cells hierarchy compared to all cells using T-Statistic | 3.55e-04 | 200 | 31 | 3 | c24a3099e3d96d8b72f6d05286bb355d661a0377 | |
| ToppCell | LPS_anti-TNF-Epithelial_alveolar-AT_1|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 3.55e-04 | 200 | 31 | 3 | 8683445ad5b70748c4a1f12eb77d47623085147e | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA---|Macroglial / cells hierarchy compared to all cells using T-Statistic | 3.55e-04 | 200 | 31 | 3 | 4fc3de4bff7ed2bf40b38462c4b4e9b87af6a4ca | |
| ToppCell | Lung_Parenchyma-Severe-Epithelial-Epithelial-Club|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 3.55e-04 | 200 | 31 | 3 | 30d428510c68da96c7c8cfd472f449ebb9631132 | |
| ToppCell | LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_only / Treatment groups by lineage, cell group, cell type | 3.55e-04 | 200 | 31 | 3 | 2dadf317a42a7e27cc1fac74f91b806c93a57108 | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA-|Macroglial / cells hierarchy compared to all cells using T-Statistic | 3.55e-04 | 200 | 31 | 3 | f17b5a54e8f9eba9dcd0808ba4e8d275ac41bce2 | |
| ToppCell | Macroglial-Polydendrocytes-PDGFRA--|Macroglial / cells hierarchy compared to all cells using T-Statistic | 3.55e-04 | 200 | 31 | 3 | cc3409518f8b436ea92deb955e81114b3f410ff7 | |
| ToppCell | Macroglial-Polydendrocytes|Macroglial / cells hierarchy compared to all cells using T-Statistic | 3.55e-04 | 200 | 31 | 3 | 961858738ce35db8760c8c2e136f8369bc444ccf | |
| ToppCell | Bronchus_Control_(B.)-Epithelial-TX-Club|Bronchus_Control_(B.) / Sample group, Lineage and Cell type | 3.55e-04 | 200 | 31 | 3 | 292c63693eb7f435335a8cfba07aa35b72139393 | |
| ToppCell | Bronchial-NucSeq-Epithelial-Epi_submucosal-gland|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 3.55e-04 | 200 | 31 | 3 | 85c0f038bcfb42669dca2b80273b0f8a1421405e | |
| ToppCell | Hippocampus-Neuronal-Inhibitory-iN2(Gad1Gad2)-Nnat-Inhibitory_Gad1Gad2_Htr3a.Nnat_(Interneuron,__(candidate_CGE-derived_1))-|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 6.91e-04 | 56 | 31 | 2 | 45241df25dfb0374e387391f7f6ea9d8d2564356 | |
| ToppCell | Hippocampus-Neuronal-Inhibitory-iN2(Gad1Gad2)-Nnat-Inhibitory_Gad1Gad2_Htr3a.Nnat_(Interneuron,__(candidate_CGE-derived_1))|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 6.91e-04 | 56 | 31 | 2 | 8e988e3b2c034f0418d90f2be35c42bd181b044f | |
| ToppCell | Hippocampus-Neuronal-Inhibitory-iN2(Gad1Gad2)-Nnat|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 6.91e-04 | 56 | 31 | 2 | 7fb4d1ee114f5ee481775bb5b6fee424147642db | |
| Disease | coronary aneurysm | 6.07e-06 | 35 | 30 | 3 | EFO_1000881 | |
| Disease | attention deficit hyperactivity disorder | 2.69e-05 | 354 | 30 | 5 | EFO_0003888 | |
| Disease | serum gamma-glutamyl transferase measurement | 2.73e-04 | 914 | 30 | 6 | EFO_0004532 | |
| Disease | response to TNF antagonist, joint damage measurement | 2.95e-04 | 25 | 30 | 2 | EFO_0004653, EFO_0005413 | |
| Disease | uridine measurement | 4.86e-04 | 32 | 30 | 2 | EFO_0010546 | |
| Disease | blood molybdenum measurement | 6.87e-04 | 38 | 30 | 2 | EFO_0007582 | |
| Disease | Gastric Adenocarcinoma | 9.63e-04 | 45 | 30 | 2 | C0278701 | |
| Disease | heart rate variability measurement, response to antipsychotic drug | 1.01e-03 | 46 | 30 | 2 | EFO_0008003, GO_0097332 | |
| Disease | Tourette syndrome | 1.19e-03 | 50 | 30 | 2 | EFO_0004895 | |
| Disease | obesity (implicated_via_orthology) | 1.34e-03 | 215 | 30 | 3 | DOID:9970 (implicated_via_orthology) | |
| Disease | alcohol dependence measurement | 1.44e-03 | 55 | 30 | 2 | EFO_0007835 | |
| Disease | schizophrenia (implicated_via_orthology) | 2.18e-03 | 68 | 30 | 2 | DOID:5419 (implicated_via_orthology) | |
| Disease | joint damage measurement | 2.18e-03 | 68 | 30 | 2 | EFO_0005413 | |
| Disease | anorexia nervosa | 2.31e-03 | 70 | 30 | 2 | MONDO_0005351 | |
| Disease | cleft lip | 2.96e-03 | 284 | 30 | 3 | EFO_0003959 | |
| Disease | eye color | 3.79e-03 | 90 | 30 | 2 | EFO_0003949 | |
| Disease | ankylosing spondylitis | 3.87e-03 | 91 | 30 | 2 | EFO_0003898 | |
| Disease | S-7-hydroxywarfarin measurement | 5.60e-03 | 110 | 30 | 2 | EFO_0803329 | |
| Disease | Drug Use Disorders | 6.10e-03 | 115 | 30 | 2 | C0013222 | |
| Disease | Drug Dependence | 6.10e-03 | 115 | 30 | 2 | C1510472 | |
| Disease | Drug habituation | 6.10e-03 | 115 | 30 | 2 | C0013170 | |
| Disease | Substance Dependence | 6.10e-03 | 115 | 30 | 2 | C0038580 | |
| Disease | Substance Use Disorders | 6.10e-03 | 115 | 30 | 2 | C0038586 | |
| Disease | Substance-Related Disorders | 6.10e-03 | 115 | 30 | 2 | C0236969 | |
| Disease | Drug abuse | 6.10e-03 | 115 | 30 | 2 | C0013146 | |
| Disease | Organic Mental Disorders, Substance-Induced | 6.10e-03 | 115 | 30 | 2 | C0029231 | |
| Disease | Prescription Drug Abuse | 6.10e-03 | 115 | 30 | 2 | C4316881 | |
| Disease | Substance abuse problem | 6.20e-03 | 116 | 30 | 2 | C0740858 | |
| Disease | atrial fibrillation | 6.22e-03 | 371 | 30 | 3 | EFO_0000275 | |
| Disease | response to vaccine | 6.84e-03 | 122 | 30 | 2 | EFO_0004645 | |
| Disease | white matter microstructure measurement | 7.14e-03 | 390 | 30 | 3 | EFO_0005674 | |
| Disease | FEV/FEC ratio | 7.41e-03 | 1228 | 30 | 5 | EFO_0004713 | |
| Disease | alcohol consumption measurement | 7.77e-03 | 1242 | 30 | 5 | EFO_0007878 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| ISNAGSGLLSHSSTL | 791 | Q4VCS5 | |
| LSSSSGSLSLSHGSS | 1281 | O15013 | |
| LSSLSGSHSGETLPL | 1691 | Q96PZ7 | |
| SSLSGSHTGESLPLA | 1686 | Q7Z408 | |
| SLLSSLSGSHSGESL | 1826 | Q7Z407 | |
| TAESHSLSGSLTGSL | 506 | P54646 | |
| SLSGSLTGSLTGSTL | 511 | P54646 | |
| SGSLLSGSTGSSLHT | 366 | Q8IV13 | |
| DSGLSLDSSHSPSSL | 476 | Q14494 | |
| LSSHGSSSSLHLGGL | 641 | Q8TB72 | |
| STSLSEALSSGHSGV | 2066 | Q8WXI7 | |
| LDTSTTLSQGGTHST | 5286 | Q8WXI7 | |
| ELSSSSGLGLHGSSS | 1421 | Q7RTP6 | |
| ELGSTHTAGATSSLT | 201 | Q7Z434 | |
| HSLSSELTGTCSLLG | 116 | P38570 | |
| NLTSSHSLLSRSGLS | 311 | P98177 | |
| DLSSGSLSSLSSRGH | 16 | Q9H5P4 | |
| SLSSLSSRGHLGSDS | 21 | Q9H5P4 | |
| LSSTSLASGHSVRLG | 196 | Q9BZL6 | |
| LLSLHSRGGSSSESS | 36 | P54368 | |
| PSLSSHGSSSSLNLG | 761 | Q14671 | |
| LLGADGHLLSTSLST | 906 | Q53TQ3 | |
| SLLSSASATVGHGLT | 136 | Q8IWE2 | |
| THRLASGLSTTSLNS | 376 | Q8TDW5 | |
| GLSSSSSLSSHTAGV | 241 | Q5MJ70 | |
| SSTLSGPDLAGHSSS | 1111 | Q9H6K5 | |
| LVHGSSLSLVSSTSS | 1666 | Q8IVL1 | |
| LLSHSSSIESLSPGG | 1561 | Q13023 | |
| SSLGSLASSRGSLNT | 441 | Q6AWC2 | |
| LTTTNQHSSSLGGLS | 666 | Q14157 | |
| TLSHSSSLLHSLGSV | 396 | Q12767 | |
| ANSSSSLHSLGSVSL | 311 | Q8IZW8 | |
| GLEGDHLSDTSTTSL | 156 | P12272 | |
| SSHLEETGSDSGTLL | 1536 | Q5T5U3 |